AbbVie is a research-based biopharmaceutical company focused on developing and marketing innovative therapies in several key therapeutic areas including immunology, oncology, neuroscience, and ophthalmology.
The recently matured and fully redeemed bond, identified by ISIN USU0029QAR75 and CUSIP U0029QAR7, was issued by AbbVie, a prominent global biopharmaceutical company established in 2013 as a spin-off from Abbott Laboratories, which specializes in the research, development, and commercialization of advanced therapies across various therapeutic areas including immunology, oncology, and neuroscience, with this specific US-issued obligation, boasting a total issuance size of $4,000,000,000 and a minimum purchase size of $2,000, having carried a fixed annual interest rate of 4.05% payable semi-annually in USD, reaching its maturity on November 20, 2039, at which point it was repaid at its market price of 100%, having previously been assigned a BBB+ credit rating by Standard & Poor's (S&P).
|